Dr Ashley Rosko speaks to ecancer about updates in haematology.

She highlights ageing as a significant risk factor for hematologic malignancies.

New FDA drugs target older adults with blood cancer, while studies like IMerge and Beat AML focus on treatment benefits and risk stratification.

Clonal haematopoiesis and geriatric risk factors for non-relapse mortality are discussed.

Additionally, new CAR T indications for relapse follicular lymphoma are introduced, emphasising the optimisation of CAR T therapy in clinical settings.